Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

Mesenchymal stem cell therapy - Jiuzhitang Maker Cell Technology

Next Previous
Drug Profile

Mesenchymal stem cell therapy - Jiuzhitang Maker Cell Technology

Alternative Names: hBMMSC; Human Bone Marrow-derived Mesenchymal Stem Cell Therapy - Jiuzhitang Maker(Beijing) Cell Technology; it-hMSC

Latest Information Update: 15 Sep 2026

Price :
$50 *
Note:
  • Adis is an information provider. We do not sell or distribute actual drugs.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase.
  • A link to download a PDF version of the drug profile will be included in your email receipt.

At a glance

  • Originator Jiuzhitang Maker (Beijing) Cell Technology
  • Class Mesenchymal stem cell therapies; Skin disorder therapies; Stem cell therapies
  • Mechanism of Action Cell replacements
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity No

Highest Development Phases

  • Phase II Pulmonary alveolar proteinosis
  • Phase I/II Ischaemic stroke

Most Recent Events

  • 20 May 2026 Efficacy and adverse events data from a phase II trial in Pulmonary alveolar proteinosis presented at the 122nd International Conference of the American Thoracic Society (ATS-2026)
  • 17 Sep 2025 Jiuzhitang Maker (Beijing) Cell Technology plans a phase I trial for Autism spectrum disorder (In children, In adolescents, In adults, In the elderly) in September 2025 (IV) (NCT07177677)
  • 02 Nov 2023 Jiuzhitang Maker (Beijing) Cell Technology in collaboration with the first affiliated hospital of Guangzhou Medical University plans a phase II trial for Pulmonary alveolar proteinosis in November 2023 (NCT06111846)

You need to be a logged in or subscribed to view this content

Request demo (opens in a new window)
If your organization or you do not have a subscription, try one of the following: If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top